

Legislative Fiscal Office

Only Impacts on Original or Engrossed Versions are Considered Official

Prepared by: MaryMichelle Sosne

Reviewed by: Haylee Morse-Miller, John Terpening, Tom MacDonald, Steve Robbins, Michael Graham, Julie Neburka

Date: 6/17/2023

Measure Description:

Replaces “naloxone” with “short-acting opioid antagonist” and updates provisions related to administration and distribution of short-acting opioid antagonists. Updates provisions relating to minors and substance abuse treatment, as well as the distribution of drug testing tools and drug paraphernalia.

Government Unit(s) Affected:

Task Force/Committee/Workgroup, Department of Education, Department of State Police, School Districts, Mental Health Regulatory Agency, Board of Pharmacy, Oregon Health Authority, Judicial Department

Analysis:

The proposed legislation has been determined to have

MINIMAL EXPENDITURE IMPACT

on state or local government.

While this individual measure has a “Minimal” fiscal impact, an agency may incur a net fiscal impact greater than minimal depending on the cumulative impact of all measures enacted into law that affect the agency.